Xiamen Innovax Biotech Co., Ltd. (Innovax) today announced its participation in the 37th International Papillomavirus Conference (IPVS 2025), taking place from October 23 to 26, 2025, in Bangkok, Thailand. In addition to hosting Booth 9, Innovax will present in a symposium—for the first time to the global academic community—the 34-month Phase III clinical data for the world's second HPV 9-valent vaccine, Cecolin 9, along with its localization strategy and implementation in Thailand.

A central element of Innovax's participation is a dedicated symposium titled “A New Era of HPV Vaccines: The Efforts from Developing Country Manufacturers for Global Cervical Cancer Elimination”, scheduled for October 23 from 12:45 to 13:45 local time (GMT+7). The session will convene leading global HPV experts to explore how technological innovation and localization strategies can accelerate progress toward the World Health Organization (WHO)’s goal of eliminating cervical cancer by 2030.

As the world’s most authoritative academic conference in the field of papillomavirus research, IPVS brings together top epidemiologists, virologists, clinicians, and public health policymakers. Innovax’s prominent role at the conference underscores China’s growing contribution to global vaccine innovation, offering “Chinese wisdom and solutions” across the entire value chain—from R&D and production to supply and accessibility, in the global fight against HPV.

Innovax warmly welcomes all conference participants, partners, and media representatives to:

·Visit us at Booth 9 to connect and explore opportunities for collaboration.

·Attend the symposium on October 23 at 12:45 (GMT+7) to join critical dialogues on the new era of HPV prevention.

About the International Papillomavirus Society (IPVS):

Since its foundation, the purpose of the International Papillomavirus Society (IPVS) has been to promote worldwide exchange of ideas, knowledge, and research materials among basic, clinical and public health research professionals concerned with human and animal papillomaviruses and their associated diseases. IPVS also strives to facilitate research, and to promote the translation of research results into new clinical applications and public health policies. IPVS serves as the organizational structure for the field of biomedical scientists, physicians and other health care providers engaged in all manner of papillomavirus research, who have met since 1975, and annually since 1982.

About Xiamen Innovax Biotech Co., Ltd. (Innovax):

As one of the leading vaccine manufacturers in China, Xiamen Innovax Biotech Co., Ltd. (Innovax) was founded in 2005 and has been dedicated to human vaccine development, manufacturing and commercialization for nearly 20 years. As a wholly owned subsidiary of Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (Wantai BioPharm), a public listed company in China (Stock Code: 603392), Innovax’s mission is to provide high-quality and affordable vaccines to improve human well-being.

Innovax has developed a unique recombinant virus-like particle (VLP) vaccine platform based on Escherichia coli, leveraging this cutting-edge technology to successfully launch the world’s first recombinant hepatitis E vaccine (Hecolin) and the world’s second HPV bivalent vaccine (Cecolin). In 2025, Innovax’s HPV 9-valent vaccine (Cecolin 9) was approved in China, which is the world’s second HPV 9-valent vaccine. Innovax never stops advancing in innovation for life.

For more information, please visit Innovax's official website: https://www.xiameninnovax.com/, and follow us on LinkedIn (@Xiamen Innovax Biotech Co., Ltd.) and X (@Innovax).